Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
12:50pm, Wednesday, 16'th Apr 2025
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
01:00am, Tuesday, 15'th Apr 2025
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig
Why You Shouldn't Bet Against Sanofi (SNY) Stock
10:10am, Friday, 11'th Apr 2025
Sanofi (SNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
01:11pm, Tuesday, 08'th Apr 2025
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
12:30pm, Thursday, 03'rd Apr 2025
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
12:08pm, Thursday, 03'rd Apr 2025
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
01:00am, Thursday, 03'rd Apr 2025
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
07:00am, Wednesday, 02'nd Apr 2025
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
10:45am, Tuesday, 01'st Apr 2025
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
04:07pm, Friday, 28'th Mar 2025
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot
US FDA approves Sanofi's bleeding disorder therapy
02:27pm, Friday, 28'th Mar 2025
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents b
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
09:44am, Friday, 28'th Mar 2025
AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
02:00am, Friday, 28'th Mar 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
12:55pm, Wednesday, 26'th Mar 2025
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
03:10am, Wednesday, 26'th Mar 2025
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
